Press conference involving POSC and major company
Seite 1 von 3
neuester Beitrag: 15.09.10 11:42
|
||||
eröffnet am: | 23.04.10 20:21 von: | 0815ax | Anzahl Beiträge: | 55 |
neuester Beitrag: | 15.09.10 11:42 von: | 0815ax | Leser gesamt: | 18669 |
davon Heute: | 4 | |||
bewertet mit 2 Sternen |
||||
![]() ![]() |
--button_text--
interessant
|
witzig
|
gut analysiert
|
informativ
|
Press conference involving POSC and major company may be announced as early as next Monday |
Written by Staff and Wire Reports |
Friday, 23 April 2010 05:48 |
Following up on the rumors we have been chasing for two weeks, it appears that staffers at Positron Corporation (OTCBB:POSC) have been busy making arrangements for a soon to be announced press conference. This news according to multiple sources who also told BioMedReports on Thursday that an official announcement about "a big development for the company" may be issued as early as Monday.Yesterday, prices took a hit after a blogger made false and defamatory accusations against not only BioMedReports, but the company as well. This is the second time that the blogger has attacked BioMedReports's and owners of this website intend to take swift and complete legal action against the owner/author of that web site. Thus far, after multiple requests, the author of the website has refused to provide us with his legal contact information so that our legal department can commence those actions. The fact remains that POSC is an established company that has been in business for over a quarter of a century and that a positive announcement- apparently worthy of a press conference- will be made public in the coming days. Speculation continues that a multi-billion dollar company trading on the NYSE at over $50 per share has taken an interest in the company. Furthermore, sources at the company tell BioMedReports that pending orders for their FDA approved, Frost and Sullivan award winning imaging system run at least "over one hundred deep." As we told subscribers two days ago, we fully expect the stock price to see substantial gains (beyond the initial 43% gains seen immediately after our trade alert) as it now appears that the company had positioned itself to be the clear leader in the five billion dollar molecular imaging market. Positron's PET (Positron Emission Tomography) scanner, known as the “Attrius”, has robust cardiac specific imaging software and, more importantly, is the only "PET" imaging device in the entire industry (see related story). It is clear that a positive development worthy of a full press conference (rumored arrangements place it at the Nasdaq MarketSite in New York City) may be officially announced as early as Monday. If true, naked shorters who took negative positions in the stock will not only have to cover, they will help push the stock price much higher by doing so. Developing... |
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
Written by M.E.Garza
Thursday, 22 April 2010 00:00
http://biomedreports.com/articles/most-popular/...ews-may-follow.html
Positron Corporation (OTC BB: POSC.OB) has been around for 27 years, but now it finally looks ready to move to the next level. It speaks volumes that recently, the company became the recipient of the “2010 Frost & Sullivan North American Molecular Imaging Systems New Product Innovation Award.”
Frost & Sullivan is a global research organization of 1,800 analysts and consultants who monitor more than 300 industries and 250,000 companies. The New Product Innovation Award is a prestigious recognition and validation of Positron Corporation’s accomplishments (see the chart below to see previous winners of the Frost & Sullivan award), but they may not be the only group ready to acknowledge the company and their technologies.
Rumors of a lucrative buy-out or partnership have been swirling around the company during the past two weeks. Multiple sources told BioMedReports, that details about "a big announcement involving Positron and a much larger, publicly traded NYSE company worth at least $25 billion" could come as early as next Monday.
We reached out to Positron's Chariman of the Board, Patrick G. Rooney and the head of the small molecular imaging company focused on Nuclear Cardiology has confirmed that his company "is currently in discussions with a potential partner in our industry."
Rooney refused to offer any assurances or details about when an agreement might be reached.
As we told subscribers yesterday, the stock price may see substantial gains now that the company had positioned itself to be the leader in the five billion dollar molecular imaging market. Positron's PET (Positron Emission Tomography) scanner, known as the “Attrius”, has robust cardiac specific imaging software and, more importantly, is the only "PET" imaging device in the entire industry (see related video).
Triggered by our alert, shares rose over 43% yesterday, but further confirmation about interest in the micro-cap company could easily send shares into the multiple dollar range.
In a letter to shareholders last month, Rooney informed investors that "Positron has several immediate opportunities with some of the largest companies in the nuclear medicine industry. Any combination of success with these opportunities will have a tremendous positive present and future impact on Positron."
Rooney appears confident that his company will thrive financially given that "the cardiac business is five times greater than the oncology business."
"Everyone has a heart problem not everyone has cancer," said Rooney. "Once you have a heart issue they'll put you on some kind of imaging device to test your heart. It's just where medicine is going. Everyone over 45 or so is starting to get imaged at the first sign of any heart issues."
Last year, Positron achieved a major milestone, as its joint venture with Neusoft Medical Systems of China received FDA 510k approval on the “Attrius” PET scanner. The event signaled the beginning of Positron’s ability to market and sell its state of the art cardiac PET scanner, the Attrius, in the United States.
In addition, the company's Nuclear Pharm-Assist® technology is set to reshape the radiopharmaceutical distribution in the nuclear cardiac imaging space. Analysts believe Positron will generate extraordinary revenues selling radiopharmaceutical consumables to the large customer base that exists today for SPECT radiopharmaceuticals (7,000+ opportunities) and will leverage the same base as the SPECT industry migrates to PET as the #1 cardiac imaging modality in the world.
"The device is like a large refrigerator that is an automated virtual pharmacy," explains Rooney. "The way the world works now, is that if you are looking for an image of your heart, your doctor calls the radio pharmacy and they order a dose syringe cocktail. It arrives and you get an injection with it. Currently, companies like Cardinal Health and GE Healthcare control this market and radio pharmacies deliver the radio pharmaceuticals. What our device does is that it compounds what you need on site, so literally we can install these devices at your cardiologist's office and when you walk in, they don’t say 'Hey, come back tomorrow so we can order you a does of radioactivity. With us, you hit some buttons and it comes out of this vending machine, if you will.
"So now literally, instead of opening up brick and mortar for $3 million and selling pharmaceuticals, we can install this inexpensive automated device that is compliant with all United States regulations on exposure issues and you can literally walk in; they hit some buttons and boom! A cocktail comes out in a syringe. They inject you and you get imaged on the spot. It works in emergency rooms- obviously that would work well- but it also works in cardiology offices where it's about patient management, It provides inventory control, it lower exposure issues and, quite frankly, it lowers cost across the board because there is less drive time, less gas consumption, etc.
"We're ready to bring in the imaging, and now we can also bring in the dose dispensing. We're going to have the full solution so that we can say 'hey doctor, we'll install the PET camera as either a rental or a sell and as far as dispensing pharmaceuticals, here's your vending machine. And just like someone who puts in a vending or soft-drink machine, we sell the products and make our profits there. This device is just basically handed out. It's the same methodology and what happens is that now, we bring everything together. We can sell drugs and cameras to the cardiologist and all of it at a better price, with more efficiency and more effectiveness. That's how we deal with our market."
"What's happening here is that the future of nuclear cardiology is PET," explains Rooney. "It's been said by the Society of Nuclear Medicine and many other organizations. The future is PET for a lot of things, better medicine, more efficiency and there were some reimbursement changes on October 30, 2009. PET reimbursement was increased by 25% and SPECT Scans (Single Photon Emission Computed Tomography) was decreased by 36%. So what happens is that this deal is worth about $100 for a PET scan and a SPECT scan is now worth about $11 or $12 dollars. So now, doctors are doing 12-15 a day to make or take 20,000 dollars or more a day, 250 days a year. That's a lot of money.
"We applied for FDA approval last January 2009 and we were approved around the beginning of May of the same year and now we have literally seen this massive rush of orders from former SPECT users. Oncology groups that want to go into PET literally come to us and say 'listen you are the only PET manufacturers in the world we want to buy PET. We don't want to buy PET CT like GE , Phillips and Siemens, because it would cost three times as much and there's the exposure issue and we just don't need this monster machine to image the heart. One of the things also, is that source radio activity for SPECT is in just massively short supply. The one used for PET is not an issue. So now doctors are saying: 'The slap in the face was the reimbursement issue. Now it's like a real kick in the pants because we can't even image because we can't get the drugs to image our patients. Thus, PET is coming on even faster and faster."
Is it any wonder the bigger players want in on the game that Positron controls so tightly? What is that worth to them? What will it be worth to investors?
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
Friday, April 23, 2010
http://chasingthealpha.blogspot.com/2010/04/...n-of-positron-inc.html
With recent events around Positron Corp. causing quite the circus, I thought it would be wise to chime in about the value they offer through their products. Recently, thru BMR's text alerts, we were notified that there will be an announcement of POSC's big news conference on Monday. ( See biomedreports.com )
POSC has been at the center of many takeover rumors and it is important to look into what kind of price we could be talking about.
Some have estimated anywhere from $0.50 - $3 pps. We should try and give POSC as fair a valuation as possible.
With that said, for POSC to sell at 0.50, or about $200-220 million, would be a significant undervaluation. The purchasing company would make this back in under 5 years with selling a conservative number of about 45-50 per year of the Attrius. (We should also note the Nuclear Pharm-Assist should also start garnering some attention.) While pps estimate of $3 or more, significantly up the time till a company will see a return on investment(ROI), since it would cost nearly $1.2 billion at the $3 price point. They would have to sell significantly more than 50 per year and continue that for at 7 years. However, we can't deny the fact that at some point the Attrius will make it to overseas markets.
Frankly, I am more comfortable with estimates in the range of $1-2. This seems to be more in line with the broader economy and the ROI timeframe for those respectable prices. This would put a pricetag in between $400-800 million. This range allows for more conservative sales estimates to be met and a better time frame to recover the initial investment.
Obviously, we should rule out the proposition of them being partnered with a larger company. Frankly, I have not found any of these types of deals. Medical imaging companies have tended to be eaten up by larger companies. I don't quite know how the royalties or licensing works for these types of partnerships.
The value of PET scans
Now, with PET scans becoming more standard and the Attrius does not require vast amounts of shielding, they should be able to sell far more than that. Also, the need for PET scans has increased due to a better understanding of the value they add in diagnostics. A PET scan helps doctors see how the organs and tissues inside your body are actually functioning.
The problem with PET/CT scanners is the added costs. The machines cost $2 million to $4 million to install, including structural renovations. Not all health care facilities can afford the machine plus the costs of renovation. The Attrius also has much lower radiation dosing than most PET/CT scanners on the market. There has obviously been a lot of concern about radiation exposure in the wake of GE and Siemens problems. Definitely something that increases it's value.
I believe some of the value added in facilities acquiring the Attrius or a company acquiring POSC, is they are opening up other markets. GE/Siemens/Phillips are going to have a tough time selling their CT/PET scanners to smaller facilities, that just can not afford the costs. That is where POSC can really capitalize. They are really pushing forward with this plan as seen by their recent presentation at a large physicians meeting, the MedAxiom Spring Conference.
"Positron Corporation (OTCBB:POSC - News) a molecular imaging solutions company focused on Nuclear Cardiology, will showcase their Attrius™ PET system at MedAxiom’s Spring Conference in Washington D.C., April 16th-18th (www.medaxiom.com).
MedAxiom is the largest service provider, information resource and networking organization exclusively for cardiology practices, representing over 5400 physicians and 300 Cardiology practices across the United States.
The MedAxiom Spring Conference targets 5400 physicians covering 45 states with approximately 65% of current attendees being CEO’s and other high-level administrators, and the other 35% being cardiologists. “We now have over 250 attendees from over 123 practices from across the United States registered, our highest attendance to date, emphasizing the importance of these kinds of meetings. We’re anticipating another great conference,” says Chris Romeo, Vice President of Corporate Relations for MedAxiom.
The MedAxiom conferences keep its members informed of changing trends, technologies, strategies and best practices in cardiology-practice administration and service delivery. These meetings allow experts, member practices and industry partners to come together to achieve truly extraordinary results for practice optimization. The conferences consist of both large-group presentations including all members and breakout sessions for small-group discussions on more specific issues.
Positron will sponsor a Partner Spotlight Luncheon, Saturday, April 17th, titled: Cardiac PET – The Present and Future of Perfusion Imaging.
Joseph Oliverio, Chief Technology Officer of Positron states, “Cardiac PET is emerging as the preferred nuclear cardiology imaging modality and Positron looks forward to educating the MedAxiom attendees of the benefits of adding Positron’s Attrius PET to their practice.” Mr. Oliverio further states, “The MedAxiom conference will demonstrate the market shift from SPECT to PET. Positron looks to deliver its Attrius™ and PET solutions to MedAxiom’s cardiology practices as their membership represents the leaders in the cardiology. Positron has the only dedicated PET system in the marketplace and expects to meet the unprecedented market demand with significant sales as a result of our corporate sponsorship.”
http://finance.yahoo.com/news/...c-PET-bw-784388101.html?x=0&.v=1
http://biomedreports.com/articles/most-popular/...te-posc-rumors.html
http://biomedreports.com/articles/most-popular/...ews-may-follow.html
Posted by Patrick at 9:51 AM
##################################################
@ Otto...: ja!
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
bmr.com:
See the Subscriber Only section for the trade alert which may take this $.20 company to the multiple dollar level at BioMedReports.com
bmr.com:
Alert: Sources tell BiomedReports that POSC has scheduled a news conference. Announcement pending.
bmr.com:
Alert: POSC news conference will be held at Nasdaq Market Site according to those sources.
bmr.com:
POSC will not deny that news conference will be announced by Monday.
bmr.com:
Alert: If POSC news conference is announced by Monday, dramatic rise in stock price is expected.
bmr.com:
BiomedReports stands behind these reports 100%. Shorts will have to cover!
bmr.com:
Alert: POSC's big news conference will be officially announced on Monday. Full details at BioMedReports.Com
http://biomedreports.com/
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
bmr_textalerts.jpg
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
Optionen
Antwort einfügen |
Boardmail an "OttomanRosendahl" |
Wertpapier:
Positron
|
Media and Investors are Invited to the MarketSite, New York City, Wednesday, May 5, 2010, 1:00pm EDT
Press Release Source: Positron Corporation On Monday April 26, 2010, 10:35 am
http://finance.yahoo.com/news/...n-to-pz-3431900783.html?x=0&.v=1
NEW YORK, April 26, 2010 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC - News), a molecular imaging solutions company focused on Nuclear Cardiology, today announced that its CEO Patrick Rooney and senior executives will present at the NASDAQ MarketSite in Times Square, New York City, NY.
They will discuss new initiatives and recent highlights including their Frost & Sullivan 2010 North American New Product Innovation Award for their Attrius PET Scanner.
When: May 5, 2010, 1:00 pm EDT
Where: NASDAQ MarketSite, 4 Times Square, New York, NY
RSVP required for building security: 212 699-0999 or christina.flood@muncmedia.com
Positron Corporation executives will be available for interviews. Please call 917 / 680 - 6011 to schedule.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. As a prominent player in the cardiac imaging industry, Positron maintains associations and relationships with multiple industry associations including the Academy of Molecular Imaging, American College of Cardiology, American Society of Nuclear Cardiology and Society of Nuclear Medicine. Positron, founded in 1983, is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com.
Forward-Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
Contact:
MUNCmedia
Christi Flood, Communications & Marketing Manager
212-699-0999
Christina.flood@muncmedia.com
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
When: May 5, 2010, 1:00 pm EDT
Where: NASDAQ MarketSite, 4 Times Square, New York, NY
http://finance.yahoo.com/news/...n-to-pz-3431900783.html?x=0&.v=1
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
Updated: POSC to present at Nasdaq Marketsite |
Written by Staff and Wire Reports |
Monday, 26 April 2010 06:45 |
The following was released by the company via press release this morning: When: May 5, 2010, 1:00 pm EDT Where: NASDAQ MarketSite, 4 Times Square, New York, NY |
biomedreports.com/articles/most-popular/37303-posc-to-present-at-nasdaq-marketsite.html
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
Updated CEO Interview Coming Tomorrow |
Written by M.E.Garza |
Tuesday, 27 April 2010 09:39 |
As we told you last week, it is expected that some very positive developments will be highlighted and that the company will emerge as the clear leader in molecular imaging devices/software for cardiology in the United States and internationally. Some key details about a big partnership which will be revealed at the press conference can not be discussed until early May, but we fully expect that the stock will trade higher as the press conference date approaches in anticipation of that news and our interview with the CEO will attempt to put some of those topics and their effects on the company's market-cap in perspective. Text of today's company's press release is below: Positron Corporation (OTCBB:POSC), a molecular imaging solutions company focused on Nuclear Cardiology, today announced that its CEO Patrick G. Rooney and senior executives will present at the NASDAQ MarketSite in Times Square, New York City, NY. Topics to include: The Company will introduce business initiatives and certain strategic alliances with industry leading companies and will address how certain opportunities will impact the industry and the Company. Senior Executives will discuss the Company's leadership role in the Nuclear Medicine industry and the immediate demand driving Cardiac PET (positron emission tomography) as a result of many positive industry factors pushing Cardiac PET as the preferred nuclear cardiology imaging modality. In addition, Positron Executives will discuss the Company's revolutionary radiopharmaceutical distribution devices as to how they enable disintermediation by manufacturers, wholesalers and consumers alike. Additional information will be given about the Company's patient injection device as it applies to patient care and worker safety with oncology and cardiology therapeutic and diagnostic radiopharmaceuticals. When: May 5, 2010, 1:00 pm EDT Where: NASDAQ MarketSite, 4 Times Square, New York, NY |
biomedreports.com/articles/most-popular/37866-updated-ceo-interview-coming-tomorrow.html
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
Zeitpunkt: 28.04.10 15:46
Aktion: Löschung des Beitrages
Kommentar: Löschung auf Wunsch des Verfassers
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
Positron CEO: "It will be evident that we are set to become the leaders in the Cardiac PET market" |
Written by Staff and Wire Reports |
Wednesday, 28 April 2010 04:30 |
![]() BiomedReports: I know you can’t get into too many details about some of the news that you’ll be discussing at the upcoming press conference, but are a few things you can share with us? Rooney: I think we want to bring to market, exactly the position that the company is in. We do have some big important strategic alliances that we will be talking about for the first time. Some of them are already in contract form and we cannot discuss them until after early May, and others involve radiopharmaceutical companies that will be getting into the radiopharmaceutical market with us, in other words, they have the drug, but they may not have the device to image this drug on. BiomedReports: Sounds like your company is suddenly getting a lot of attention? Rooney: The cardiac PET industry is in the beginning of a massive upswing. BiomedReports: Why is that? For one, it’s better medicine. All the leading medical organizations have really gotten behind the cardiac PET technology. Organizations like the Society of Nuclear Cardiology, The American College of Cardiology, The American Society of Nuclear Cardiology, basically the whole nuclear cardiology industry has really put the endorsement stamp on Cardiac PET. (Note: Cardiac PET (or cardiac positron emission tomography) is a form of diagnostic imaging in which patients are evaluated using a PET scanner after intravenously injected with a radioisotope. This form of diagnostic imaging has traditionally been perceived as cost-prohibitive in comparison to general nuclear medicine cardiac stress testing using single photon emission computed tomography (SPECT). However, due to significant gains in access to scanners, related to the widely accepted role of PET/CT in clinical oncology, cardiac PET is now set to become more widely available, particularly given various clinical and technical advantages that will make this a potential test of choice in the diagnosis of coronary artery/heart disease.) The standard of care throughout history has been SPECT, but really it’s inferior to our PET technology. The financial reimbursement for these services from places like CMS; Medicare and Medicaid have just increased PET Reimbursement and decreased SPECT reimbursement. So in the past, where cardiac imaging was, PET versus SPECT, 99% of the 18 million exams per year were done with a SPECT imaging system. BiomedReports: Why? Rooney: Because there was a massive distribution of SPECT cameras, the drugs were more readily available and reimbursement is comparable. Also, a SPECT camera cost much less than a PET camera. BiomedReports: What’s changed? Rooney: A few things, actually. The first thing is that now all of reimbursement money from insurers and Medicare/Medicaid has increased for PET and decreased for SPECT. These insurers are now pushing physicians to a better imaging modality, a better medical practice. BiomedReports: Why are they doing that? Rooney: Simply because it’s better and it actually saves them money in the long run. They’ve all said ‘We’ll pay more to get better imaging now.’ It helps everyone down the line. This bodes well for POSC, I would imagine because our company is the only dedicated Cardiac PET manufacturer in the world. There is no one else. Siemens, Philips Medical and GE Healthcare make PET CTs – those are oncology based; primarily, oncology based. In other words, they can be for cardiac, but there’s radiation exposure, they’re too expensive and actually, they’re too large. Their machines cost more than twice what ours does. I believe that’s a fair number and encompasses a range. The other thing that has occurred is that there is a worldwide shortage of Moly, or Molybdenum (also known widely as Mo 99), which is necessary isotope used for SPECT imaging. It’s the primary drug used in SPECT imaging procedures. So SPECT imaging has just taken another hit, if you will and we’re seeing physicians in droves move away from SPECT sooner and going to PET. (Note: Molybdenum is mined as a principal ore, and is also recovered as a byproduct of copper and tungsten mining. On May 18, 2009, the National Research Universal (NRU) reactor in Chalk River, Ontario—operated by Atomic Energy of Canada Limited (AECL)—was taken offline for immediate repair after a heavy water leak was found at the base of the reactor vessel. The NRU reactor is one of the world’s major molybdenum 99 (Mo 99) supply sources; Mo 99 is the raw material used to produce a key isotope used in medical imaging procedures. According to AECL, the reactor normally supplies about 50 percent of the Mo 99 used globally for diagnostic nuclear medicine studies. The U.S. and Canadian medical communities are most affected by the current shortage. With only five major Mo 99 reactors around the globe, and the Chalk River facility producing roughly half of the world’s supply, the situation means Mo 99 will be in short supply.) During the past three years, different reactors have been offline unexpectedly for extended periods of time, creating vast Mo 99 shortages. [See the informative PDF document at the FDA government site authored by Covidien (NYSE: COV)] This change from SPECT to PET is all happening sooner than most expected. The evolution was already happening, but the reimbursement and Moly shortages have really taken things up a notch. During the last three months alone, requests for proposals (for equipment pricing and purchases) at our company from the medical industry have increased three-fold. The recent volcano incident has made a bad situation even worse. They just had a two week shut down in Europe where no Moly was being shipped, so that’s how sensitive the situation has become. You need drugs to image the patient. There is nothing you can do without them. BiomedReports: What about the isotope you use in your machines? Rooney: By contrast, the PET isotope is not in short supply. Quite frankly it is very readily available. These are some of the many factors that we’ll be discussing in more detail at our upcoming press conference. Our competitors, which are really like comparing apples to oranges, are getting hammered. I mean really hammered. BiomedReports: How else has this affected your company and the future prospects of business? On the PET side, we are now working on some significant strategic alliances which we will talk about. For example, one of our new markets that has very few PET systems in it is the Canadian market. We look to be selling a significant amount of systems in Canada. With a population of 38 million plus, that is a large market for us to be expanding into. Compared to the United States, it’s a smaller market, but what’s nice is that we are the only dedicated cardiac PET manufacturer in the world, so the expansion opportunities will continue. We plan on being a leader in the market place not only here in the U.S. (where the market opportunities call for four to six thousand machines), but also outside the U.S. There will be an announcement shortly that will impact those markets opportunities for us in a substantial way. BiomedReports: What are some of your challenges going forward? Rooney: One of our biggest challenges is that we’re unknown to most of Wall Street. We’ve been around for 27 years, but that’s mostly been as an academic company. Now it’s a true business enterprise with a market place that is now completely pro PET and in the need of our technology. The stars have aligned. BiomedReports: Your business also has a pharma side. What can you tell us about that? On the pharmaceuticals side, we are now working with a number of companies on our automated dose dispensing device. We’ve talked about some of that that as part of the upcoming presentation at the press conference. We have these revolutionary dose dispensing devices which automate, yet comply with exposure regulations while still allowing us to expand and enhance the distribution of radiopharmaceuticals (radioactive pharmaceuticals used in the field of nuclear medicine as tracers in the diagnosis and treatment of many diseases). These machines are designed for use in both oncology and radiopharmaceuticals. BiomedReports: What will these developments do for the value or market cap of the company? When we say that we will be leaders of this Cardiac Pet market, I think that will be evident to everyone within the next few months. Positron is clearly the pioneer in Positron Emission Tomography. We’re the first name in PET. Now our technology has received some validation with the big awards that we’ve been given and by the fact that PET is now the future of radiocardiology. |
biomedreports.com/articles/most-popular/38004-positron-ceo-qit-will-be-evident-that-we-are-set-to-become-the-leaders-in-the-cardiac-pet-marketq.html
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
http://www.marketwire.com/press-release/...-Announcements-1155132.htm
CEO of Positron Corporation Bullish About Upcoming Press Conference Announcements
LOS ANGELES, CA--(Marketwire - April 28, 2010) - Patrick G. Rooney, the Chariman of the Board of Positron Corporation (OTCBB: POSC) -- a molecular imaging company focused on Nuclear Cardiology -- has confirmed in an interview with BioMedReports that his company is about to grow significanlty given various new partnerships and shifting market conditions: "When we say that we will be leaders of this Cardiac Pet market, I think that will be evident to everyone within the next few months."
"The standard of care throughout history has been SPECT technology, but really it's inferior to our PET technology," explains Rooney. "The financial reimbursement for these services from places like CMS, Medicare and Medicaid have just increased PET Reimbursement and decreased SPECT reimbursement."
"The first thing is that now all of reimbursement money from insurers and Medicare/Medicaid has increased for PET and decreased for SPECT. These insurers are now pushing physicians to a better imaging modality, a better medical practice.
"The other thing that has occurred is that there is a worldwide shortage of Moly, or Molybdenum (also known widely as Mo 99), which is a necessary isotope used for SPECT imaging. It's the primary drug used in SPECT imaging procedures. So SPECT imaging has just taken another hit, if you will and we're seeing physicians in droves move away from SPECT sooner and going to PET."
During the last three months alone, requests for proposals at Positron have increased three-fold, according to the CEO.
Positron recently won the 2010 Frost and Sullivan "North American Molecular Imaging Systems New Product Innovation Award."
The complete special report is available at BioMedReports.com
http://biomedreports.com/articles/most-popular/...ac-pet-marketq.html
Biotech investors interested in accessing the news portal's database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
About BioMedReports.com
BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.
For more biomedical sector and investment news go to http://BioMedReports.com
Media Contact:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail: Email Contact
Tel: +1 323 472 4480
Fax: +1 888 210 3556
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
News Coming |
Written by Staff and Wire Reports |
Wednesday, 28 April 2010 10:56 |
Apparently, today's special interview with the CEO has caused a number of calls to the company for more information regarding the impact of potential revenues for POSC, etc and the company will be addressing some of those topics on Thursday morning. As we reported yesterday, we fully anticipate that the stock will trade higher in anticipation of next week's already announced pressw conference which is to take place at the Nasdaq MarketSite in New York City. Traders love forward looking news events that drive stock prices higher and since the company has already told us that they are not going to be doing anything like dilutive financing, the light is green for further upward action in the coming days. The stock price shot up over 38% as of the printing of this article after CEO Patrick Rooney's exclusive ineterview with BioMedReports, in which he stated that his company is now poised to become the leader of the lucrative Cardiac Pet market place. "I think that will be evident to everyone within the next few months," said Rooney. |
biomedreports.com/articles/subscriber-only-content/38076-news-coming.html
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
29.04.2010 14:47
http://www.finanznachrichten.de/...industry-leading-companies-004.htm
Positron Corporation (OTCBB:POSC) is a molecular imaging solutions company focused on Nuclear Cardiology states that its proprietary product line also includes unique solutions for the oncology community designed to enhance its position in this industry.
The Company's Nuclear Pharm-Assist®, an automated radiopharmaceutical dose dispensing device aims to greatly transform the way healthcare providers serve patients seeking care for numerous cardiac and cancer diseases.
The innovative device has been attracting significant new partners by streamlining the production, dispensing and delivery of radiopharmaceuticals.
"We believe Positron's dose dispensing device will revolutionize the way radiopharmaceuticals are compounded and distributed in the US and around the world. Positron's products, services and position in the marketplace provide an economical, efficient and regulatory compliant solution in the multibillion dollar per year radiopharmaceutical consumables industry," said Positron's CEO Patrick G. Rooney. "While most in the industry already know that PET is the future of nuclear cardiology, we fully expect that an equal to greater amount of revenue and profits will be generated by our new proprietary automated radiopharmaceutical device as it is used in both the cardiac and oncology sectors."
Through automation procedures which are normally manually performed by technologists, pharmacists and staff, Positron's platform is able to expedite and deliver difficult to handle and transport doses at medical treatment facilities of all sizes. At the same time, the Nuclear Pharm-Assist®, meets the strictest guidelines for radiation exposure and is designed as a platform for compliance with United States Pharmacopeia regulations (USP 797).
Next week, the Company is scheduled to address investors and discuss Positron and the nuclear medicine industry's demand for its products and how current and future opportunities will significantly impact the industry and the Company.
Positron Corporation's Press Conference
When: May 5, 2010, 1:00 pm EDT
Where: NASDAQ MarketSite, 4 Times Square, New York, NY
RSVP required for building security: 212 699-0999 or christina.flood@muncmedia.com
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. As a prominent player in the cardiac imaging industry, Positron maintains associations and relationships with multiple industry associations including the Academy of Molecular Imaging, American College of Cardiology American Society of Nuclear Cardiology and Society of Nuclear Medicine. Positron founded in 1983, is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
Contacts:
Positron Corporation
Patrick G. Rooney, (317)576-0183
© 2010 Business Wire
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
Update: POSC Chart Says... |
Written by M.E.Garza |
Thursday, 29 April 2010 04:27 |
Yesterday, the stock rebounded +43.75% after our interview with CEO Pat Rooney. The shorts had gotten hold of it (coupled with several bad market days) and if the run continues upward in anticipation of next week's press conference, as expected, many of those shorts will have to continue to cover. This morning's positive press release, in which the company reveals it's expectations that the new radiopharmaceutical business should generate as much revenue- if not more- than as it's core PET business, should help that push. Said CEO Pat Rooney in this morning's release: "While most in the industry already know that PET is the future of nuclear cardiology, we fully expect that an equal to greater amount of revenue and profits will be generated by our new proprietary automated radiopharmaceutical device as it is used in both the cardiac and oncology sectors." It is now widely rumored that a large cap NYSE company trading at around $50 per share has already tapped this tiny micro-cap company for a partnership or strategic alliance. Perhaps that partnership involves the company's new technology. Another look:
|
biomedreports.com/articles/most-popular/38194-posc-chart-says.html
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
Positron's CEO Believes Impact of New Technology and Partnerships Will Make Company Significantly More Profitable Than Ever |
Written by M.E.Garza |
Friday, 30 April 2010 03:19 |
While his candid comments to us appeared bold and optimistic, his estimates apparently did not include some of the resources and capabilities that will be brought to the table for POSC by some of the partnerships that are about to be announced publicly. "In 2008, we acquired a company in Indianapolis and this company brought us two things, they brought us pharmaceutical expertise and they brought us a device that looked like a large, fat refrigerator. What this device does is pretty incredible. It’s an automated virtual pharmacy. "We will be profitable this year, much more profitable next year and so on- year over year going forward; and that doesn’t include some of the resources and capabilities that will be brought to the table by some of the partnerships that are about to be announced. Once you add those relationships, the revenue and profit numbers increase significantly. It’s very significant.” Company shares gained 48% after Rooney's comments to BioMedReports two days ago, before giving up $.02 in Thursday's trading action. Analysts expect that shares will continue to trend higher as we get closer to Wednesday's press conference in New York. |
biomedreports.com/articles/most-popular/38340-positron-ceo-believes-impact-of-new-technology-and-partnerships-will-make-company-significantly-more-profitable-than-ever.html
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|
Optionen
Antwort einfügen |
Boardmail an "OttomanRosendahl" |
Wertpapier:
Positron
|
Folks…this is an incredible situation and could be one of the best investments this decade. It is already the largest investment I’ve made in any one company. I believe huge things will be happening starting next week. I also expect additional deals, partnerships and numerous new orders as early as next week. Finally, I think POSC will be in the $3.00-$5.00 per share range by the end of this year. Please see these important highlights from Friday AM’s Press Release below:
1. Positron will be VERY profitable this year.
2. Positron CEO sees the company being “MUCH More Profitable Next Year and so on, year over year going forward”.
3. These growth estimates DO NOT include the revenue about to be announced next week from the partnerships.
4. “Once you add those relationships, the revenue and profit numbers increase significantly. It's very significant." (I expect revenue growth to be exponential by 4Q2010 and certainly next year. 300-800% growth? Yes, these are easily attainable and reasonable with the expected partnerships about to be announced).
5. Positron has already inked a deal with a “yet to be announced multi-billion dollar NYSE company”.
6. Positron has received calls in been in discussions with several other publicly traded, big cap companies as well.
7. Positron has started staffing and hiring much faster than ever before and much sooner than anticipated.
8. Positron’s business plan has materialized much faster and more intensely than ever expected.
Good luck to all...except there is no luck needed. All that's needed is smart investing. And buying in now is about as smart as you can be.
Optionen
Antwort einfügen |
Boardmail an "OttomanRosendahl" |
Wertpapier:
Positron
|
http://chasingthealpha.blogspot.com/2010/05/...nd-why-you-should.html
all other articles about POSC here
http://chasingthealpha.blogspot.com/search/label/POSC
Optionen
Antwort einfügen |
Boardmail an "OttomanRosendahl" |
Wertpapier:
Positron
|
Media and Investors are Invited to the MarketSite, New York City, Wednesday, May 5, 2010, 1:00pm EDT
Tuesday May 4, 2010, 8:30 am
http://finance.yahoo.com/news/...tion-pz-1939556903.html?x=0&.v=1
NEW YORK, May 4, 2010 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC - News), a molecular imaging solutions company focused on Nuclear Cardiology, today announced that its CEO Patrick Rooney and senior executives will present at the NASDAQ MarketSite in Times Square, New York City, NY.
Topics to include: updates on new business initiatives, strategic alliances and global distribution partnerships.
Senior executives will also discuss the company's leadership driving Cardiac PET's (positron emission tomography) expanding dominance as the preferred nuclear cardiology imaging modality over legacy technology SPECT (single-photon emission computerized tomography). Positron has the only dedicated PET system in the marketplace.
When: May 5, 2010, 1:00 pm EDT
Where: NASDAQ MarketSite, 4 Times Square, New York, NY
RSVP required for building security: 917-680-6011, bradley.smith@muncmedia.com
Webcast:
CLICK HERE to schedule webcast in your calendar. Click "open" and the "Save and Close" when prompted.
CLICK HERE to watch the event May 5, 1:00pm
Positron Corporation executives will be available for interviews. Please call 917-680-6011 to schedule.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. As a prominent player in the cardiac imaging industry, Positron maintains associations and relationships with multiple industry associations including the Academy of Molecular Imaging, American College of Cardiology American Society of Nuclear Cardiology and Society of Nuclear Medicine. Positron founded in 1983, is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
Contact:
MUNCmedia
Bradley Smith
917-680-6011
bradley.smith@muncmedia.com
*amM - keine Kaufempfehlung
Optionen
Antwort einfügen |
Boardmail an "0815ax" |
Wertpapier:
Positron
|